TW201241182A - Method of production of sialylated antibodies - Google Patents

Method of production of sialylated antibodies Download PDF

Info

Publication number
TW201241182A
TW201241182A TW101106076A TW101106076A TW201241182A TW 201241182 A TW201241182 A TW 201241182A TW 101106076 A TW101106076 A TW 101106076A TW 101106076 A TW101106076 A TW 101106076A TW 201241182 A TW201241182 A TW 201241182A
Authority
TW
Taiwan
Prior art keywords
ser
val
thr
pro
lys
Prior art date
Application number
TW101106076A
Other languages
English (en)
Chinese (zh)
Inventor
Francis Blanche
Beatrice Cameron
Bruno Genet
Fabienne Soubrier
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of TW201241182A publication Critical patent/TW201241182A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41Glycosylation, sialylation, or fucosylation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW101106076A 2011-02-24 2012-02-23 Method of production of sialylated antibodies TW201241182A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11305200 2011-02-24
EP11306090 2011-09-01

Publications (1)

Publication Number Publication Date
TW201241182A true TW201241182A (en) 2012-10-16

Family

ID=45774189

Family Applications (1)

Application Number Title Priority Date Filing Date
TW101106076A TW201241182A (en) 2011-02-24 2012-02-23 Method of production of sialylated antibodies

Country Status (6)

Country Link
US (1) US20140046032A1 (OSRAM)
EP (1) EP2678357A1 (OSRAM)
JP (1) JP2014508759A (OSRAM)
AR (1) AR085302A1 (OSRAM)
TW (1) TW201241182A (OSRAM)
WO (1) WO2012113863A1 (OSRAM)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
RU2708314C2 (ru) * 2013-03-11 2019-12-05 Джензим Корпорейшн Гипергликозилированные связывающие полипептиды
HK1207960A1 (en) 2013-03-12 2016-02-19 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
WO2014149067A1 (en) 2013-03-15 2014-09-25 Momenta Pharmaceuticals, Inc. Methods related to ctla4-fc fusion proteins
ES2802274T3 (es) * 2013-05-02 2021-01-18 Momenta Pharmaceuticals Inc Glicoproteínas sialiladas
EP2996772B1 (en) 2013-05-13 2018-12-19 Momenta Pharmaceuticals, Inc. Methods for the treatment of neurodegeneration
CA2908407C (en) * 2013-05-29 2022-06-14 F. Hoffmann-La Roche Ag Quantitative control of sialylation
HK1221741A1 (zh) 2013-07-05 2017-06-09 F. Hoffmann-La Roche Ag 用於使用N-末端截短的β-半乳糖苷-α-2,6-唾液酸转移酶变体的糖蛋白的单-和二唾液酸化的方法
EP2824176A1 (en) * 2013-07-11 2015-01-14 Siamed'xpress Methods for producing sialylated therapeutic proteins
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
WO2015057622A1 (en) 2013-10-16 2015-04-23 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
EP3129067B1 (en) 2014-03-19 2023-01-04 Genzyme Corporation Site-specific glycoengineering of targeting moieties
CN108064266A (zh) 2014-07-21 2018-05-22 格利科斯芬兰公司 在丝状真菌中具有哺乳动物样n-聚糖的糖蛋白的制备
EP3037527A1 (en) * 2014-12-22 2016-06-29 F. Hoffmann-La Roche AG Sialyltransferase without CMP-dependent sialidase activity
WO2016102436A1 (en) 2014-12-22 2016-06-30 F. Hoffmann-La Roche Ag Cmp-dependent sialidase activity
EP3544612A4 (en) 2016-11-23 2020-05-13 Acetylon Pharmaceuticals, Inc. PHARMACEUTICAL COMBINATIONS COMPRISING A HISTONE DEACETYLASE INHIBITOR AND A CD38 INHIBITOR AND METHODS OF USING THE SAME
EP3354278A1 (en) * 2017-01-31 2018-08-01 Sanofi Neuronal cell protective effect of antibodies specific for the protofibrillar form of the beta-amyloid peptide
FR3080376B1 (fr) * 2018-04-20 2022-12-09 Lab Francais Du Fractionnement Autoanticorps hautement sialyles et leurs utilisations
CA3135032A1 (en) 2019-04-03 2020-10-08 Genzyme Corporation Anti-alpha beta tcr binding polypeptides with reduced fragmentation
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
TW202325853A (zh) * 2021-11-09 2023-07-01 美商安進公司 治療性蛋白之生產
WO2025101901A1 (en) * 2023-11-10 2025-05-15 The Board Of Trustees Of The Leland Stanford Junior University Use of sialylated ivig or igg fc region-containing protein for preventing or treating respiratory virus diseases

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5474896A (en) 1992-05-05 1995-12-12 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US5792632A (en) 1992-05-05 1998-08-11 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5830729A (en) 1996-04-18 1998-11-03 Institut Pasteur I Sce I-induced gene replacement and gene conversion in embryonic stem cells
US20020045207A1 (en) * 1997-10-31 2002-04-18 Lynne A. Krummen Glycoprotein production process
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
JP5362164B2 (ja) 2000-07-07 2013-12-11 バイオアークティック ニューロサイエンス アーベー アルツハイマー病の予防及び治療
AU2002333832B2 (en) 2001-09-14 2007-07-26 Cellectis Random integration of a polynucleotide after in vivo linearization
WO2004067753A2 (en) 2003-01-28 2004-08-12 Cellectis Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof.
AU2006265676B2 (en) * 2005-06-30 2013-01-24 Centocor, Inc. Methods and compositions with enhanced therapeutic activity
PL1945665T3 (pl) 2005-10-21 2012-02-29 Genzyme Corp Leki oparte na przeciwciałach z ulepszoną aktywnością adcc
US20080206246A1 (en) 2006-04-05 2008-08-28 Ravetch Jeffrey V Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
RU2551782C2 (ru) 2005-12-12 2015-05-27 Ац Иммуне Са Специфические в отношении амилоида бета (а бета) 1-42 моноклональные антитела, обладающие терапевтическими свойствами
AU2007235413B2 (en) 2006-04-05 2012-08-02 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
JP2010512306A (ja) * 2006-10-27 2010-04-22 ザ ロックフェラー ユニバーシティー 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法
AU2007317755A1 (en) 2006-10-27 2008-05-15 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
CL2007003411A1 (es) 2006-11-28 2008-07-04 Centelion Proteina fusion que consiste en una region fc de una inmunoglobulina con un fragmento o dominio soluble de un receptor para fgf; polinucleotido que la codifica y vector y celula que lo comprenden; composicion farmaceutica que comprende la proteina fu
HUE037489T2 (hu) 2007-08-29 2018-08-28 Sanofi Sa Humanizált anti-CXCR5 antitestek, azok származékai és alkalmazásuk
CA2701790A1 (en) 2007-10-05 2009-04-16 Ac Immune S.A. Use of humanized anti-beta-amyloid antibody in ocular diseases
KR20100075639A (ko) 2007-10-15 2010-07-02 센토코 오르토 바이오테크 인코포레이티드 인간 항-아밀로이드 항체, 조성물, 방법 및 용도
US8586706B2 (en) 2007-10-25 2013-11-19 Kagoshima University Peptide vaccine using mimic molecules of amyloid β peptide
US8936936B2 (en) 2007-10-25 2015-01-20 Sangamo Biosciences, Inc. Methods and compositions for targeted integration
CN104098695B (zh) 2007-10-29 2018-09-07 道健康生活医药株式会社 抗体及其应用
BRPI0819312A2 (pt) 2007-11-16 2020-09-15 The Rockefeller University específico anticorpo para a forma protofibril de proteínas amilóide beta
NZ586003A (en) 2007-12-11 2012-08-31 Glaxo Group Ltd Antigen binding proteins that bind beta-amyloid peptide
EP2233502A1 (en) 2009-03-27 2010-09-29 Deutsches Rheuma-Forschungszentrum Berlin Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them
FR2945538B1 (fr) * 2009-05-12 2014-12-26 Sanofi Aventis Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
US10087236B2 (en) * 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering

Also Published As

Publication number Publication date
WO2012113863A1 (en) 2012-08-30
EP2678357A1 (en) 2014-01-01
AR085302A1 (es) 2013-09-18
JP2014508759A (ja) 2014-04-10
US20140046032A1 (en) 2014-02-13

Similar Documents

Publication Publication Date Title
TW201241182A (en) Method of production of sialylated antibodies
AU2018266711B2 (en) Anti-CD3-binding domains and antibodies comprising them, and methods for their generation and use
JP7765397B2 (ja) 新規抗lilrb4抗体および派生産物
CA2946503C (en) Modified antigen binding polypeptide constructs and uses thereof
JP5511686B2 (ja) 抗cd4抗体
KR20100074220A (ko) Cdr의 아미노산 치환에 의해 항체의 등전점을 개변하는 방법
CA2963760A1 (en) Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
KR102669686B1 (ko) 변형된 항원 결합 폴리펩티드 작제물 및 이의 용도
TW200808830A (en) Mutant polypeptide having effector function
TWI781973B (zh) 用於以活體外進行抗體糖基化工程之方法
KR20140108520A (ko) CD1d에 대한 항체
CN119685431A (zh) 用于体外糖工程化抗体的方法
MX2013015061A (es) Anticuerpo anti-cxcr4 con funciones efectoras y su uso para el tratamiento del cancer.
JP2024112905A (ja) 抗体依存性細胞介在性細胞傷害の調節方法
TW201441258A (zh) 用於hiv預防及治療的醣修飾抗cd4抗體
US20250277041A1 (en) Anti-fgfr2 adcc enhanced antibody and use thereof
US20250101104A1 (en) Bispecific molecule with tunable affinity to a targeted antigen
CN118414356A (zh) 具有增强的效应子功能的生物合成单价结合分子
JP7245793B2 (ja) 安定化したキメラFab
US20250206824A1 (en) GLYCOENGINEERED Fc VARIANT POLYPEPTIDES WITH ENHANCED EFFECTOR FUNCTION
US20250263481A1 (en) Monoclonal Antibodies Against CLDN18.2 and FC-Engineered Versions Thereof
RU2832921C1 (ru) Модифицированные антигенсвязывающие полипептидные конструкции и их применение
TW202405000A (zh) Sars-cov2抗體及其用途
CN118475614A (zh) 具有增强的效应子功能的生物合成双互补位或双特异性结合分子
HK40011892B (zh) 用於体外糖工程化抗体的酶的再使用